{"organizations": [], "uuid": "17637b4db43d3020002c08ca724178f5a8ff8aba", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-roivant-sciences-and-arqule-enter/brief-roivant-sciences-and-arqule-enter-into-license-agreement-for-derazantinib-in-china-idUSFWN1PX111", "country": "US", "domain_rank": 408, "title": "BRIEF-Roivant Sciences And Arqule Enter Into License Agreement For Derazantinib In China", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-07T14:07:00.000+02:00", "replies_count": 0, "uuid": "17637b4db43d3020002c08ca724178f5a8ff8aba"}, "author": "", "url": "https://www.reuters.com/article/brief-roivant-sciences-and-arqule-enter/brief-roivant-sciences-and-arqule-enter-into-license-agreement-for-derazantinib-in-china-idUSFWN1PX111", "ord_in_thread": 0, "title": "BRIEF-Roivant Sciences And Arqule Enter Into License Agreement For Derazantinib In China", "locations": [], "entities": {"persons": [], "locations": [{"name": "china", "sentiment": "none"}, {"name": "taiwan", "sentiment": "none"}, {"name": "macau", "sentiment": "none"}, {"name": "hong kong", "sentiment": "none"}], "organizations": [{"name": "arqule inc", "sentiment": "none"}, {"name": "derazantinib in china reuters staff", "sentiment": "none"}, {"name": "arqule", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "arqule inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 7, 2018 / 12:07 PM / in 11 minutes BRIEF-Roivant Sciences And Arqule Enter Into License Agreement For Derazantinib In China Reuters Staff \nFeb 7 (Reuters) - Arqule Inc: \n* ROIVANT SCIENCES AND ARQULE ENTER INTO LICENSE AGREEMENT FOR DERAZANTINIB IN CHINA \n* ARQULE INC - ‍DEAL TERMS INCLUDE AN UPFRONT PAYMENT TO ARQULE OF $3 MILLION AND AN ADDITIONAL $2.5 MILLION DEVELOPMENT MILESTONE WITHIN FIRST YEAR​ \n* ARQULE INC - ARQULE IS ALSO ELIGIBLE FOR REGULATORY AND COMMERCIAL MILESTONES AND ROYALTIES ON FUTURE SALES OF DERAZANTINIB IN GREATER CHINA \n* ARQULE INC - COLLABORATION BETWEEN CO AND ROIVANT WILL EXPAND CLINICAL DEVELOPMENT OF DERAZANTINIB \n* ARQULE - ‍ GRANTED A ROIVANT UNIT AN EXCLUSIVE LICENSE TO DEVELOP, COMMERCIALIZE DERAZANTINIB IN PEOPLE‘S REPUBLIC OF CHINA, HONG KONG, MACAU, TAIWAN​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-07T14:07:00.000+02:00", "crawled": "2018-02-07T14:21:26.006+02:00", "highlightTitle": ""}